Diversify Advisory Services LLC Trims Stock Holdings in Edwards Lifesciences Corporation $EW

Diversify Advisory Services LLC trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,229 shares of the medical research company’s stock after selling 6,719 shares during the period. Diversify Advisory Services LLC’s holdings in Edwards Lifesciences were worth $1,763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. True Wealth Design LLC lifted its position in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares during the period. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in Edwards Lifesciences during the third quarter worth $30,000. Finally, Strengthening Families & Communities LLC purchased a new stake in Edwards Lifesciences during the third quarter worth $34,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Evercore reissued an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Finally, Piper Sandler reissued an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Trading Up 3.2%

Edwards Lifesciences stock opened at $84.21 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The stock has a market cap of $48.91 billion, a PE ratio of 46.02, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. The stock has a 50-day moving average of $82.51 and a two-hundred day moving average of $81.49. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 71,444 shares of company stock worth $6,035,269. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.